Chemotherapy and radiotherapy for mesothelioma

Recent Results in Cancer Research

Volumn 189, Issue , 2011, Pages 127-147

  Dhalluin, Xavier ^a,b   Scherpereel, Arnaud ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c INSERM U1019   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; IRINOTECAN; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; RANPIRNASE; RIBONUCLEASE INHIBITOR; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CREATININE CLEARANCE; DECORTICATION; DIARRHEA; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUSHING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE; LUNG RESECTION; LUNG TOXICITY; MALIGNANT MESOTHELIOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PATIENT SAFETY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TUMOR SEEDING; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; ASBESTOS; COMBINED MODALITY THERAPY; GENE THERAPY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MESOTHELIOMA; PLEURAL NEOPLASMS; QUINAZOLINES; RIBONUCLEASES; THALIDOMIDE;

EID: 79954999135     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10862-4_8     Document Type: Article

References (103)

1. Ahamad A, Stevens CW et al (2003) Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 55(3): 768-775 (Pubitemid 36170016)
2. Alberts AS, Falkson G et al (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6(3):527-535 (Pubitemid 18090702)
3. Allen AM, Den R et al (2007) Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 68(5):1366-1374 (Pubitemid 47176807)
4. Baas P, Boogerd W et al (2005) Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48(2):291-296
5. Baldini EH, Recht A et al (1997) Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63(2): 334-338 (Pubitemid 27084548)
6. Ball DL, Cruickshank DG (1990) The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 13(1):4-9 (Pubitemid 20114548)
7. Belani CP, Adak S et al (2004) Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer 6(1):43-47 (Pubitemid 39199285)
8. Berghmans T, Paesmans M et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2):111-121 (Pubitemid 35157753)
9. Bolden JE, Peart MJ et al (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784 (Pubitemid 44348499)
10. Boutin C, Rey F et al (1995) Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108(3):754-758
11. British Thoracic Society (2007) BTS statement on malignant mesothelioma in the UK, 2007. Thorax 62(Suppl 2):ii1-ii19
12. Bydder S, Phillips M et al (2004) A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 91(1):9-10 (Pubitemid 39013037)
13. Byrne MJ, Davidson JA et al (1999) Cisplatin and gemcitabine treatment or malignant mesothelioma: a phase II study. J Clin Oncol 17(1): 25-30 (Pubitemid 29022374)
14. Candelaria M, Gallardo-Rincon D et al (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18(9):1529-1538 (Pubitemid 47365487)
15. Castagneto B, Botta M et al (2008) Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19(2):370-373 (Pubitemid 351201722)
16. Catalano A, Romano M et al (2002) Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene 21(18):2896-2900 (Pubitemid 34499388)
17. Ceresoli GL, Zucali PA et al (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24(9): 1443-1448 (Pubitemid 46622011)
18. Ceresoli GL, Castagneto B et al (2008) Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99(1):51-56 (Pubitemid 351920240)
19. Cortese JF, Gowda AL et al (2006) Common EGFR mutations conferring sensitivity to geftinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118(2):521-522 (Pubitemid 41779097)
20. Crisanti MC, Wallace AF et al (2009) The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8(8):2221-2231
21. DeVita VT Jr (1983) The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51(7):1209-1220 (Pubitemid 13161097)
22. Emami B, Lyman J et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109-122
23. Fennell DA, JP CS et al (2005) Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47(2):277-281 (Pubitemid 40089485)
24. Fizazi K, Doubre H et al (2003) Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21(2):349-354 (Pubitemid 46606165)
25. Flores RM, Krug LM et al (2006) Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 1(4):289-295 (Pubitemid 47163979)
26. Garland LL, Rankin C et al (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol 25(17):2406-2413 (Pubitemid 46999211)
27. Govindan R, Kratzke RA et al (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11(6):2300-2304 (Pubitemid 40490190)
28. Gregoire M, Ligeza-Poisson C et al (2003) Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21(7-8):791-794 (Pubitemid 36091999)
29. Gupta V, Mychalczak B et al (2005) Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63(4):1045-1052 (Pubitemid 41505282)
30. Gupta V, Krug LM et al (2009) Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 4(6):746-750
31. Hegmans JP, Hemmes A et al (2005) Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 171(10):1168-1177 (Pubitemid 40663731)
32. Hegmans JP, Veltman JD et al (2010) Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 181(12):1383-90
33. Hillerdal G, Sorensen JB et al (2008) Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 3(11): 1325-1331
34. Holsti LR, Pyrhonen S et al (1997) Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol 36(4):397-405 (Pubitemid 27298560)
35. Hopkins-Donaldson S, Cathomas R et al (2003) Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 106(2):160-166 (Pubitemid 36835166)
36. Jackman DM, Kindler HL et al (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113(4):808-814
37. Janne PA, Wozniak AJ et al (2006) Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 1(6):506-512 (Pubitemid 47181396)
38. Janne PA, Simon GR et al (2008) Phase II trial of pemetrexed and gemcitabine in chemotherapynaive malignant pleural mesothelioma. J Clin Oncol 26(9):1465-1471
39. Jassem J, Ramlau R et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698-1704
40. Katirtzoglou N, Gkiozos I et al (2010) Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 11(1):30-35
41. Kelly WK, O'Connor OA et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17): 3923-3931 (Pubitemid 46218695)
42. Kindler HL, Vogelzang NJ, Chien K, Stadler WM, Karczmar G, Heimann R, Vokes EE (2001) SU 5416 in malignant mesothelioma: a University of Chicago Phase II Consortium Study. 2001 ASCO meeting. Proc Am Soc Clin Oncol 20:2001 (abstract 1359)
43. Kindler HL, Herndon JE et al (2005) Irinotecan for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 48(3):423-428 (Pubitemid 40693629)
44. Kindler HL, Karrison T, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes EE (2007) Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma (MM). J Clin Oncol ASCO meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:7526
45. Kristensen CA, Nottrup TJ et al (2009) Pulmonary toxicity following IMRT after extra-pleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 92(1):96-99
46. Krug LM, Pass HI et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007-3013
47. Kruklitis RJ, Singhal S et al (2004) Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 127(1):123-130 (Pubitemid 38160475)
48. Lee TT, Everett DL et al (2002) Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124(6):1183-1189 (Pubitemid 35417006)
49. Li Q, Yano S et al (2007) The therapeutic effcacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodefcient mice. Clin Cancer Res 13(19):5918-5925 (Pubitemid 47583920)
50. Li L, Razak AR et al (2009) Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option? Lung Cancer 64(2):207-210
51. Maasilta P (1991) Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 20(3):433-438
52. Maggi G, Casadio C et al (2001) Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 19(3):346-350 (Pubitemid 32197443)
53. Manegold C, Symanowski J et al (2005) Secondline (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16(6):923-927 (Pubitemid 40903918)
54. Mathy A, Baas P et al (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50(1):83-86 (Pubitemid 41297473)
55. Mikulski SM, Costanzi JJ et al (2002) Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20(1):274-281 (Pubitemid 34032621)
56. Miles EF, Larrier NA et al (2008) Intensitymodulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71(4):1143-1150
57. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K, Boyer MJ (2003) Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. 2003 ASCO meeting. Proc Am Soc Clin Oncol 22:2003 (abstract 912)
58. Muers MF, Stephens RJ et al (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371(9625):1685-1694 (Pubitemid 351671885)
59. Nakas A, Trousse DS et al (2008) Open lungsparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 34(4):886-891
60. Niyikiza C, Baker SD et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1(7):545-552
61. Nowak AK, Byrne MJ et al (2002) A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87(5):491-496
62. O'Brien ME, Watkins D et al (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17(2):270-275 (Pubitemid 43160117)
63. Odaka M, Sterman DH et al (2001) Eradication of intraperitoneal and distant tumor by adenovirusmediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 61(16):6201-6212 (Pubitemid 32762558)
64. Ohta Y, Shridhar V et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81(1):54-61 (Pubitemid 29415491)
65. Okuda K, Sasaki H et al (2008) Epidermal growth factor receptor gene mutation, amplifcation and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 134(10):1105-1111
66. Okuno SH, Delaune R et al (2008) A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer 112(8):1772-1779 (Pubitemid 351536837)
67. O'Rourke N, Garcia JC et al (2007) A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 84(1):18-22 (Pubitemid 47030694)
68. Otterson GA, Herndon JE II et al (2004) Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 44(2):251-259 (Pubitemid 38482058)
69. Pass HI, Kranda K et al (1997) Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4(3):215-222 (Pubitemid 127725247)
70. Pass HI, Temeck BK et al (1997) Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 4(8):628-633 (Pubitemid 127725490)
71. Pass HI, Brewer GJ et al (2008) A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86(2):383-389; discussion 390
72. Pavlakis N, Williams G et al (2002) Thalidomide alone or in combination with cisplatin/gemcitabine chemotherapy for malignant mesothelioma (MM): preliminary results from two phase II studies. Proc Am Soc Clin Oncol 2002;21, 2:p19b, Abstract 1885 38th Annual Meeting, May 18-21, 2002, Orlando FL
73. Porta C, Zimatore M et al (2005) Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48(3):429-434 (Pubitemid 40693630)
74. Portalone L, Antilli A et al (2005) Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori 91(1):15-18 (Pubitemid 40469382)
75. Ralli M, Tourkantonis I et al (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8): 3441-3444
76. Ramalingam SS, Belani CP et al (2009) Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4(1):97-101
77. Razak AR, Chatten KJ et al (2008) Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 60(2):294-297 (Pubitemid 351609136)
78. Rice DC, Stevens CW et al (2007) Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5): 1685-1692; discussion 1692-3
79. Rusch VW, Venkatraman ES (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68(5):1799-1804
80. Rusch VW, Rosenzweig K et al (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122(4):788-795
81. Santoro A, O'Brien ME et al (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3(7):756-763
82. Scherpereel A (2007) Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med 101(6):1265-1276 (Pubitemid 46671140)
83. Scherpereel A, Berghmans T et al (2011) for the European Lung Cancer Working Party (ELCWP). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J. Jan; 37(1):129-135. Epub 2010 Jun 7
84. Scherpereel A, Astoul P et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35(3):479-495
85. M. Serke, T. Bauer (2007) Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 18198 Chicago, IL 2007 June 1-4
86. Sorensen JB, Sundstrom S et al (2007) Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2(2):147-152 (Pubitemid 47181344)
87. Stahel RA, Weder W et al (2009) Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):73-75
88. Sterman DH, Recio A et al (2007) A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13(15 Pt 1):4456-4466 (Pubitemid 47219714)
89. Sterman DH, Recio A et al (2010) A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 18(4):852-860
90. Strizzi L, Catalano A et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4):468-475 (Pubitemid 32266815)
91. Tourkantonis I, Makrilia N et al (2010) Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study. Am J Clin Oncol. May 3. [Epub ahead of print]
92. Tsao AS, Mehran R et al (2009) Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 10(1):36-41
93. van Haarst JM, Baas P et al (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86(3):342-345 (Pubitemid 34187648)
94. van Meerbeeck JP, Gaafar R et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):6881-6889
95. van Sandick JW, Kappers I et al (2008) Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. Ann Surg Oncol 15(6):1757-1764
96. Velcheti V, Kasai Y et al (2009) Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol 4(4):559
97. Villano JL, Husain AM, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL (2004) A phase II trial of imatinib mesylate in patients with malignant mesothelioma. J Clin Oncol 22(14S):663
98. Vogelzang N, Taub RN, Shin D, Costanzi J, Pass H, Gutheil J, Georgiadis M, McAndrew P, Kelly K, Chun H, Mittelman A, McCachren S, Shogen K, Mikulski S (2000) Phase III Randomised Trial of Onconase (ONC) vs. Doxorubicin (DOX) in Patients (Pts) with Unresecable Malignant Mesothelioma (UMM): analysis of survival. 2000 ASCO meeting. Proc Am Soc Clin Oncol 19:2000 (abstract 2274)
99. Vogelzang NJ, Rusthoven JJ et al (2003) Phase III study o pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644 (Pubitemid 46606305)
100. Xanthopoulos A, Bauer TT et al (2008) Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 3:34
101. Yajnik S, Rosenzweig KE et al (2003) Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56(5):1319-1326 (Pubitemid 36842883)
102. Yang CT, You L et al (2003) A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 23(1A):33-38 (Pubitemid 36358497)
103. Zucali PA, Ceresoli GL et al (2008) Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112(7):1555-1561 (Pubitemid 351441168)